# EDGAR Filing Document

**Accession Number:** 0001816590
**File Stem:** 0001140361-25-039738
**Filing Date:** 2025-10
**Character Count:** 9556
**Document Hash:** cee648aae99002ef4eda2ab86c43cf9d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-039738.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001140361-25-039738

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COMPASS Pathways plc
- **CENTRAL INDEX KEY:** 0001816590
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92194
- **FILM NUMBER:** 251431469

**BUSINESS ADDRESS:**
- **STREET 1:** 3RD FLOOR, 1 ASHLEY ROAD
- **STREET 2:** ALTRINCHAM
- **CITY:** CHESIRE
- **STATE:** X0
- **ZIP:** WA14 2DT
- **BUSINESS PHONE:** 1-716-676-6461

**MAIL ADDRESS:**
- **STREET 1:** 3RD FLOOR, 1 ASHLEY ROAD
- **STREET 2:** ALTRINCHAM
- **CITY:** CHESIRE
- **STATE:** X0
- **ZIP:** WA14 2DT

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Compass Rx Ltd.
- **DATE OF NAME CHANGE:** 20200701
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ATAI Life Sciences N.V.
- **CENTRAL INDEX KEY:** 0001840904
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** PROF. J.H. BAVINCKLAAN 7
- **CITY:** AMSTELVEEN
- **PROVINCE COUNTRY:** P7
- **ZIP:** 1183
- **BUSINESS PHONE:** 49 89 2153 9035

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** PROF. J.H. BAVINCKLAAN 7
- **CITY:** AMSTELVEEN
- **PROVINCE COUNTRY:** P7
- **ZIP:** 1183

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ATAI Life Sciences B.V.
- **DATE OF NAME CHANGE:** 20210115

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**COMPASS Pathways plc**

*(Name of Issuer)*

**Ordinary Shares**

*(Title of Class of Securities)*

**20451W101**

*(CUSIP Number)*

**Ryan Barrett**<br>Prof. J.H. Bavincklaan 7<br>Amstelveen P7 1183AT<br>49 (0) 89 2153 9035

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/27/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **20451W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ATAI Life Sciences N.V.** | Name of reporting person<br>**ATAI Life Sciences N.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5785774.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5785774.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5785774.00** | Aggregate amount beneficially owned by each reporting person<br>**5785774.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6%** | Percent of class represented by amount in Row (11)<br>**6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **20451W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ATAI Life Sciences GmbH (formerly ATAI Life Sciences AG)** | Name of reporting person<br>**ATAI Life Sciences GmbH (formerly ATAI Life Sciences AG)** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares

**(b) Name of Issuer:**
COMPASS Pathways plc

**(c) Address of Issuer's Principal Executive Offices:**
33 Broadwick Street, London, X0, W1F 0DQ

This Amendment No. 5 to Schedule 13D amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the "SEC") on May 24, 2021 (as amended, the "Schedule 13D") relates to the ordinary shares, nominal value GBP 0.008 per ordinary share (the "Ordinary Shares"), of COMPASS Pathways plc, a public limited company under the laws of England and Wales (the "Issuer"). Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

CUSIP number 20451W101 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on The Nasdaq Stock Market under the symbol "CMPS." Each ADS represents one Ordinary Share of the Issuer. No CUSIP number has been assigned to the Ordinary Shares of the Issuer.

In connection with a corporate reorganization, ATAI Life Sciences AG was converted into a German GmbH in April 2025. As a result, the Ordinary Shares of the Issuer reported herein are held directly by ATAI Life Sciences N.V

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 of the Schedule 13D is amended and restated in its entirety by inserting the following information:

The information contained on the cover pages is incorporated by reference to this Item 5.

As of the date of this Schedule 13D, ATAI N.V. may be deemed to beneficially own 5,785,774 Ordinary Shares, representing approximately 6.0% of the 95,941,264 Ordinary Shares outstanding as of July 28, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed by the Issuer on July 31, 2025.

**(b)**
The information contained on the cover pages is incorporated by reference to this Item 5.

ATAI N.V. directly holds the securities reported herein.

**(c)**
During the past 60 days, ATAI N.V. effected the following open market sales of ADSs representing Ordinary Shares:

10/22/2025: 20,000 shares for $6.3194 per share.
10/23/2025: 20,000 shares for $6.2949 per share.
10/24/2025: 60,000 shares for $6.3714 per share.
10/27/2025: 60,000 shares for $6.5801 per share.
10/28/2025: 60,000 shares for $6.4946 per share.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ATAI Life Sciences N.V.

**Signature:** /s/ Anne Johnson

**Name/Title:** Anne Johnson, Chief Financial Officer

**Date:** 10/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ATAI Life Sciences GmbH (formerly ATAI Life Sciences AG)

**Signature:** /s/ Anne Johnson

**Name/Title:** Anne Johnson, Chief Financial Officer

**Date:** 10/29/2025